Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
C4 Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) to develop small-molecule medicines that eliminate disease-causing proteins. Leveraging its proprietary TORPEDO platform, the company designs oral, selective protein degraders primarily for oncology indications, including multiple myeloma, non-Hodgkin lymphoma, melanoma, colorectal, and non-small cell lung cancers. C4’s approach offers catalytic, durable, and highly selective therapies addressing unmet medical needs through innovative drug discovery and strategic collaborations.
This description was generated via AI from an annual report. Updated about 1 year ago.